PMID- 23040002
OWN - NLM
STAT- MEDLINE
DCOM- 20130404
LR  - 20220318
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 12
IP  - 5
DP  - 2012 Oct
TI  - Prognostic value of circulating tumor cells according to immunohistochemically 
      defined molecular subtypes in advanced breast cancer.
PG  - 340-6
LID - S1526-8209(12)00165-6 [pii]
LID - 10.1016/j.clbc.2012.07.001 [doi]
AB  - BACKGROUND: Breast cancer is a heterogeneous disease. Circulating tumor cell 
      (CTC) enumeration might be useful to identify different risk categories within 
      each molecular subtype. METHODS: We retrospectively analyzed 203 consecutive 
      patients with metastatic breast cancer with baseline CTC enumeration performed 
      with CellSearch (Veridex Corp, Warren, NJ) between March 2005 and July 2011. 
      Patients were categorized into 3 prognostic groups based on the number of CTCs 
      (0, 1-4, and >/= 5) and into 5 categories based on tumor biological 
      characteristics: luminal-A (estrogen receptor [ER] and progesterone receptor [PR] 
      > 1%, grade 1/2, human epidermal growth factor 2 [HER2]-negative [HER2(-)], Ki67 
      value < 14%); luminal-B (ER and/or PR > 1%, grade 3, HER2(-), Ki67 value > 14%); 
      luminal-B HER2-positive [HER2(+)] (ER and/or PR > 1%, any grade, HER2(+), Ki-67 
      value any); HER2(+) (HER2 overexpressed/fluorescence in situ hybridization [FISH] 
      amplified, ER and PR absent); triple negative (TN) (ER and PR 0%, HER2 not 
      overexpressed/FISH not amplified). RESULTS: Median age was 57 years (range 31-78 
      years). Twenty-seven patients (13.3%) had luminal-A category, 105 (51.7%) 
      patients had luminal-B, 29 (14.3%) patients had luminal-B HER2(+), 24 patients 
      (11.8%) had HER2(+), and 18 patients (8.9%) had TN. CTCs were mostly found in 
      patients with luminal-A/luminal-B HER2(-) subtype. At multivariable analysis, CTC 
      count was a significant predictive factor for overall survival (OS) in all 
      molecular subtypes (log-rank P < .01). Patients with 0 CTCs/7.5 mL blood and all 
      subtypes, except HER2(+), seem to perform better compared with other categories. 
      CONCLUSION: These findings confirm CTCs as an important prognostic factor for 
      metastatic breast cancer in all molecular subtypes. Larger studies could help 
      identify metastatic breast cancer subgroups in which CTC analysis would be 
      particularly useful.
CI  - Copyright (c) 2012 Elsevier Inc. All rights reserved.
FAU - Munzone, Elisabetta
AU  - Munzone E
AD  - Division of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy. 
      elisabetta.munzone@ieo.it
FAU - Botteri, Edoardo
AU  - Botteri E
FAU - Sandri, Maria Teresa
AU  - Sandri MT
FAU - Esposito, Angela
AU  - Esposito A
FAU - Adamoli, Laura
AU  - Adamoli L
FAU - Zorzino, Laura
AU  - Zorzino L
FAU - Sciandivasci, Angela
AU  - Sciandivasci A
FAU - Cassatella, Maria Cristina
AU  - Cassatella MC
FAU - Rotmensz, Nicole
AU  - Rotmensz N
FAU - Aurilio, Gaetano
AU  - Aurilio G
FAU - Curigliano, Giuseppe
AU  - Curigliano G
FAU - Goldhirsch, Aron
AU  - Goldhirsch A
FAU - Nole, Franco
AU  - Nole F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/classification/metabolism/*pathology
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Neoplastic Cells, Circulating/*pathology
MH  - Prognosis
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptors, Estrogen/*metabolism
MH  - Receptors, Progesterone/*metabolism
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2012/10/09 06:00
MHDA- 2013/04/05 06:00
CRDT- 2012/10/09 06:00
PHST- 2012/01/19 00:00 [received]
PHST- 2012/05/25 00:00 [revised]
PHST- 2012/07/09 00:00 [accepted]
PHST- 2012/10/09 06:00 [entrez]
PHST- 2012/10/09 06:00 [pubmed]
PHST- 2013/04/05 06:00 [medline]
AID - S1526-8209(12)00165-6 [pii]
AID - 10.1016/j.clbc.2012.07.001 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2012 Oct;12(5):340-6. doi: 10.1016/j.clbc.2012.07.001.